News and Trends 3 Oct 2022Oxford BioTherapeutics enters into antibody agreement with Genmab Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT's IO programs. The target was… October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email